NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

1 month ago

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational…

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

1 month ago

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform…

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

1 month ago

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel…

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

1 month ago

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate…

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

1 month ago

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has…

Redecan Cannabis Launches New Limited-Edition Genetics and Expands Signature ‘Wrapped & Redee’ Pre-roll Line for the Holidays

1 month ago

TORONTO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Redecan Cannabis, a leading brand under Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a…

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

1 month ago

Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE…

Positive results advance peanut tablet to phase II development

1 month ago

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding…

Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

1 month ago

Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic…

Polyrizon’s Moving Forward with Expected 2025 Clinical Trial – Entered Manufacturing Agreement for its PL-14 Allergy Blocker

1 month ago

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer…